<DOC>
	<DOC>NCT02583919</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo</brief_summary>
	<brief_title>Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male or female, age 18 to 75 BMI ≥ 25.0 kg/m2 HbA1c ≥ 8.0% and ≤ 10.5% Type 2 Diabetes Mellitus and on stable dose of Metformin Agree to conduct homebased (fasted) blood glucose testing as directed Clinically significant abnormalities in medical history of physical exam Show evidence of uncorrected hypothyroidism or hyperthyroidism hormone results History of solid organ transplant or renal dialysis History of liver disease History of greater than 3 episodes of severe hypoglycemia within 6 months of screening Treatment with any other antidiabetic drug(s) other than metformin within 3 months of screening History of diabetic ketoacidosis Any other significant illness or condition that may interfere with the patient participating or completing the study Inability or unwillingness to comply with protocol or study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>